How many email patterns does Glyscend Therapeutics use?

Glyscend Therapeutics uses 2 known email patterns.

What domain does Glyscend Therapeutics use for work emails?

Glyscend Therapeutics uses glyscend.com for work email addresses.

Most Common Email Formats at Glyscend Therapeutics

Glyscend Therapeutics's most common email format is FLast@glyscend.com (ex. JDoe@glyscend.com), used for 85% of glyscend.com addresses. Glyscend Therapeutics uses 2 email patterns.

@glyscend.com

2 patterns

Format	Example	Share of glyscend.com
FLast@glyscend.comMost common	JDoe@glyscend.com	85%
First@glyscend.com	John@glyscend.com	15%

Need a specific person's email?

Browse Glyscend Therapeutics's employee directory (about 5 employees) and reveal verified emails free.

Frequently Asked Questions

What does Glyscend Therapeutics do?

Glyscend Therapeutics was founded in 2014 and operates in the Biotechnology Research industry, alongside similar companies like Boehringer Ingelheim, Sanofi and Novo Nordisk. You can visit glyscend.com. Explore Glyscend Therapeutics's company overview page for more information.

What is Glyscend Therapeutics's email address format?

Glyscend Therapeutics's email format typically follows the pattern of FLast@glyscend.com; this email format is used 85% of the time. Other contacts within LeadIQ's database had email formats such as First@glyscend.com. Looking for more contact data? Unlock accurate emails and phone numbers from millions of profiles verified in real-time.

How many employees does Glyscend Therapeutics have currently?

Glyscend Therapeutics has approximately 5 employees as of October 2026. Key team members to contact include Director: B. S., Director, Johns Hopkins Center Neurogi: J. P. and Endocrinologist: J. V. For more team information and contact data, explore Glyscend Therapeutics's employee directory with LeadIQ.

Glyscend Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

Glyscend Therapeutics is a biotechnology research company based in Lowell, Massachusetts. It develops oral, gut-targeted polymer therapeutics intended for metabolic conditions, including type 2 diabetes. Its lead drug candidate is designed to be taken orally, remain in the gastrointestinal tract, and be non-absorbed, with the aim of replicating the metabolic effects of bariatric surgery while avoiding invasive procedures. The approach focuses on delivering therapy within the gut to influence metabolic pathways with safety advantages over surgical options.

As a small company within the biotechnology sector, Glyscend positions its work at the intersection of metabolic disease research and gut-targeted therapies. In September 2023, the company appointed Sapan A. Shah, Ph.D., as Chief Executive Officer.

Most common format

FLast@glyscend.com

Example: JDoe@glyscend.com

2 patterns. See all formats

Verify a Glyscend Therapeutics email address

Free with a LeadIQ account. No credit card.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Everything for prospecting,
in one platform.

What you can expect from LeadIQ:

B2B data verified in real-time
Sync data to your CRM, & add it to an outreach sequence in one click
Integrations with your tech stack for optimal efficiency
A patented AI cold email generator
Account & contact-level job change tracking

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Most Common Email Formats at Glyscend Therapeutics

@glyscend.com

Need a specific person's email?

Frequently Asked Questions

What does Glyscend Therapeutics do?

What is Glyscend Therapeutics's email address format?

How many employees does Glyscend Therapeutics have currently?

Glyscend Therapeutics Email Format

Ready to create more pipeline?

Everything for prospecting,in one platform.

What you can expect from LeadIQ:

Ready to create more pipeline?

Everything for prospecting,
in one platform.